Global Induced Pluripotent Stem Cell (iPS Cell) Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|誘導性多功能幹細胞(iPS細胞)的全球市場(2021年∼2028年) Global Induced Pluripotent Stem Cell (iPS Cell) Market - 2021-2028|
|出版日期: 2021年06月22日||內容資訊: 英文 180 Pages||
全球誘導多能幹細胞 (ips 細胞) 市場的增長是由 iPS 細胞療法的進步和增加的組織併購推動的，以擴大 iPSC 產品組合。研究活動的增加也是市場的主要增長因素。
The global induced pluripotent stem cell (ips cell) market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Induced pluripotent stem cells (iPS cell), immature cell generated from an adult (mature) cell and has regained the capacity to differentiate into any cell in the body. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and potentially treat previously incurable diseases.
The induced pluripotent stem cell (ips cell) market growth is driven by the increasing therapeutic advancements with iPS Cell, growing mergers and acquisitions of organizations to expand their portfolio in iPSCs, Increasing research activities are the major driving factors of the market.
Strong pipeline of iPSC is expected to drive the growth of global induced pluripotent stem cell (ips cell) market during the forecasting period.
The prevalence of chronic diseases worldwide is driving many vendors in the market to develop novel induced pluripotent stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, I Peace Inc. and Avery Therapeutics are collaborating to advance an iPSC-derived cell therapy for heart failure. I Peace is generating the GMP-grade iPSCs, while Avery Therapeutics is using them to manufacture its MyCardia. I Peace can mass production clinical-grade iPSC lines simultaneously in a single room using a miniaturized plate and robotic technology. Its facility is equipped with the fully-closed automated iPSC manufacturing system that meets the safety standards of the U.S. FDA and Japanese PMDA.
Hopstem Biotechnology is one of China's first iPSC cell therapy companies and a market leader in iPSC-derived clinical-grade cell products. In June 2021, it partnered with Neurophth Biotechnology to co-develop an iPSC-derived cell therapy to treat ocular diseases. Hopstem has a proprietary neural differentiation platform, a patented iPSC reprogramming method, and GMP manufactory and quality systems.
Some major disadvantages of iPSC are likely to hamper the market growth
The primary issue is the use of retroviruses to generate iPSCs as they are associated with cancer, and specifically, retroviruses can insert their DNA anywhere in the genome and subsequently trigger cancer-causing gene expression.
Moreover, in certain non-dividing cell types (such as PBMCs or elderly skin fibroblasts), the reprogramming rate of somatic cells to iPSCs is very low (less than 0.02 %). Thus, there is also a need to assess the quality and variability of the reprogramming process.
COVID-19 Impact Analysis
Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization's report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.
According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients and research activities are also holded. Thus, the COVID-19 pandemic has impacted the induced pluripotent stem cell (iPS Cell) market. However, the situation is expected to improve gradually.
The Human iPSCs segment is expected to hold largest share in this market segment
Animal models don't achieve perfect success results in predicting the pathophysiology of many human diseases because animals differ from humans in physiology, the immune system and individual genetic backgrounds. However, human-induced pluripotent stem cells (iPSCs) are decisive for studying neuronal activity in vitro. Furthermore, human iPSC-derived cells overcome many limitations of other popular models, such as immortalized cell lines and primary mouse neurons, which reproducibility issues can plague and lack biological relevance.
For instance, On October 08, 2020, Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance to Deliver Integrated hiPSC Drug Discovery Solutions
The drug development & discovery segment is expected to hold largest share in this market segment
iPSCs potentially transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery. For instance, BlueRock Therapeutics, a subsidiary of Bayer since August 2019, develops iPSC-derived cell therapies to target Parkinson's disease, heart failure, and ocular diseases.
North America region holds the largest market share of global induced pluripotent stem cell (iPS Cell) market
North America holds the largest market in the global induced pluripotent stem cell (iPS Cell) market. Currently, the U.S. is the largest target market for pluripotent stem cell (PSC) technology, with more than 2,800 patent families filed. This accounts for more than 50% of the total patent families filed from 2006 to the present and significant market players established in this region. Increasing investments in research & development for product innovations and a positive outlook toward industrial livestock are expected to boost the regional market share. It is widely adopted as a lean meat replacement in North American countries, especially in the U.S. For instance, Semma Therapeutics, which Vertex Pharmaceuticals acquired for $950 million in late 2019, is developing a treatment for Type 1 diabetes. This treatment consists of cells derived from iPSCs that behave like pancreatic cells.
The global induced pluripotent stem cell (ips cell) market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Axol Bioscience Ltd, Cynata Therapeutics Limited, Evotec SE, FUJIFILM Cellular Dynamics, Inc, Ncardia, Pluricell Biotech, REPROCELL USA, Inc, Sumitomo Dainippon Pharma Co., Ltd, Takara Bio, Inc, Thermo Fisher Scientific, Inc, Shenzhen Haodi Huatuo Biotechnology Co., Ltd, Wuxi Yingnuui Biomedical Technology, Shanghai Haoran Biotechnology Co., Ltd, ScienCell Research Laboratories, Inc, Beijing Lebo Biotechnology Co., Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, Cynata Therapeutics manufacturers iPSC-derived MSCs using its proprietary Cymerus™ technology. In partnership with FUJIFILM Corporation, it is clinically testing these cells for the treatment of graft-versus-host disease (GvHD). It is also conducting trials for the treatment of critical limb ischemia (CLI), osteoarthritis (OA), and respiratory failure/distress, including ARDS.
Key Companies to Watch
FUJIFILM Cellular Dynamics, Inc
Overview: FUJIFILM Cellular Dynamics, Inc. (FCDI) is a leading developer and manufacturer of human cells used in drug discovery, toxicity testing, stem cell banking, and cell therapy development and founded in 2004 by Dr. James Thomson. The Company partners with innovators worldwide to combine biologically relevant human cells with the newest technologies to drive advancements in medicine and healthier living. Its technology offers the potential to create induced pluripotent stem cells (iPSCs) from anyone, starting with a standard blood draw and followed by the powerful capability to develop into virtually any cell type in the human body.
Product Portfolio: The Company's portfolio comprised of chemical, mechanical, optical, electronic, software and production technologies.
Key Developments: On March 17, 2021, FUJIFILM Cellular Dynamics and Sana Biotechnology Announced License Agreement for the Development of iPSC-Derived Cell Therapies.
The global induced pluripotent stem cell (ips cell) market report would provide an access to an approx. 53 market data table, 43 figures and 200 pages.
Global Induced Pluripotent Stem Cell (iPS Cell) Market - By Type
Global Induced Pluripotent Stem Cell (iPS Cell) Market - By Application
Global Induced Pluripotent Stem Cell (iPS Cell) Market - By Region
LIST NOT EXHAUSTIVE